explore -WSS

explore

author：leisure time 2025-09-30 18:00:13 - browse：8756

foreign-trained health professionals — Adobe

The pharmaceutical industry has been up in arms over Medicare’s first list of 10 prescription drugs that will be subject to negotiations. But other major parts of the health care industry — hospitals, doctors, and other providers — have refrained from either lending support or criticizing the government’s process.

The American Hospital Association, the industry’s main lobbying group, told STAT it is “not commenting on this issue right now.” The American Medical Association had no comment and deferred to other physician trade groups. The Federation of American Hospitals offered no statement.

The American Health Care Association, which lobbies on behalf of nursing homes, did not comment on the list of 10 drugs or Medicare’s negotiating power. But it said in a statement that “many nursing home residents have multiple chronic conditions that require several medications, so any efforts at reducing their out-of-pocket costs would be welcome.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Ionis drug prevents swelling attacks due to hereditary angioedema

WSS

What to expect at HLTH 2023, the health care industry conference

AI can decode, harness the power of the humane immune system

What to expect at HLTH 2023, the health care industry conference

Sana to lay off nearly a third of staff, de

Bill would stop addiction treatment from triggering child abuse inquiry

Analysis of telehealth claims data suggest service duplication

focus

explore

entertainment

Cancer drug shortages should be causing more outrage

Shifting the focus from loneliness to social health

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Intellia reports positive results for its CRISPR

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Malaria cases in Florida and Texas: Here’s what you need to know

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

23andMe had bad news about my health. I wish a person had delivered it

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

knowledge

FDA authorizes Novavax’s updated Covid

Chan Zuckerberg Biohub Chicago to focus on inflammation

Senate panel eyes new effort on drug shortages

ASCO: Palliative care found as helpful given virtually as in person

Ultragenyx gene therapy for rare liver ailment succeeds in late

FDA panel signals lack of confidence in Amgen cancer drug data

hotspot

focus

focus

entertainment